Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 104, Issue 12, Pages 4399-4408Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.24629
Keywords
pharmacokinetic/pharmacodynamic models; simulation; drug interaction; cancer chemotherapy; in silico modeling
Funding
- National Natural Science Foundation of China (NSFC) [81273583]
- Pfizer scholarship for pharmacometrics
Ask authors/readers for more resources
Our study aimed at the investigation of in vivo anticancer effect of the combination use of dexamethasone (DEX) and gemcitabine (GM) as well as the development of pharmacokinetic/pharmacodynamic (PK/PD) models in MCF-7 xenograft model. Further, simulations were conducted to optimize doses and administration schedules. The inhibitory effect of different doses and administration schedules were investigated in MCF-7 xenograft model. Semi-mechanism-based PK/PD models were established based on the preclinical data to characterize the relationship between plasma concentration and the time course of the drug response quantitatively. The PK/PD models were further applied to predict and optimize doses and administration schedules, which would lead to tumor stasis by the end of the treatment. Synergistic effect was observed in the PD study in vivo and further confirmed by the estimated combination index psi obtained from PK/PD models. The optimum dose regimen was selected as DEX 2 mg/kg, qd and GM 10 mg/kg, q2d based on the simulation results. In summary, the PD interaction between DEX and GM was demonstrated as synergism by both experimental results and modeling approach. Dosage regimens were optimized as predicted by modeling and simulations, which would provide reference for preclinical study and translational research as well. (C) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available